SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.125    -0.875 (-43.75%)
Bid:
1.00
Ask:
1.25
Spread: 0.25 (25.00%)
Market Cap: £1.88m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

Lab-Grown Leather Ltd Progress

21 May 2025 07:00

RNS Number : 4970J
BSF Enterprise PLC
21 May 2025
 

 

 

London, 21 May 2025

 

BSF Enterprise PLC 

 

Lab-Grown Leather Ltd Progress

 

BSF Enterprise PLC (LSE:BSFA) a leading innovator in tissue-engineered materials is pleased to announce significant progress in its 100% owned subsidiary, Lab-Grown Leather Ltd ("LGL"), a pioneer in the development of sustainable, high-quality, lab-grown leather. LGL is applying its patented advanced tissue engineering platform (ATEP™) to create leather alternatives for high-value markets, including luxury goods, aerospace, and automotive.

Product Development Highlights

LGL is developing three core product lines:

Elemental Leather™: Premium, high-end luxury leather, identical in feel, look, and smell to traditional leather. It is 100% lab-grown, free of scaffolds and additives.

Elemental+™: High-performance, lightweight, and thin new-age leather.

Elemental X™: Novel leather enabled by engineering biology, AI, and a proprietary cell expression system. This includes the groundbreaking T-Rex leather.

Elemental+™: New Ultra-Thin and Strong Leather

LGL has achieved a significant breakthrough with Elemental+™. Traditional animal leather loses integrity and strength when processed below 0.4mm. However, Elemental+™ can be produced at an astonishing thickness of just 0.04mm - a hundred times thinner than the thickest traditional leather-while maintaining comparable strength and durability. This has been achieved using vegetable-derived tanning components, making it more environmentally friendly. This innovation, and associated new patent filing, opens new possibilities for applications in sectors where weight is critical, such as sportswear, electric vehicles, and aerospace.

Dr Che Connon of Lab-Grown Leather Ltd. stated, "Elemental+™ is a testament to the power of our Advanced Tissue Engineering Platform and our commitment to pushing the boundaries of what biofabricated materials can achieve. We've engineered a new form of leather that retains the desirable properties of traditional leather while offering a level of thinness and strength previously unattainable. This opens up entirely new design and functional possibilities for industries where every gram counts."

Elemental X: T-Rex Leather

LGL has also made substantial progress with Elemental X™, including the development of T-Rex leather. This world-first material, to be derived from synthetic T-Rex DNA, has garnered significant media attention. The leather will be grown in LGL's facilities in Newcastle upon Tyne, UK. Unlike other producers, LGL's finished leather contains no synthetic scaffolds or plastics. Elemental X leather can be made from unlimited species types (past or present). In collaboration with The Organoid Company and VML, a subsidiary of WPP plc, we will promote and scale the Lab-Grown T-Rex Leather product. Given its unique nature and limited initial availability, T-Rex leather is expected to be exclusive and priced at a substantial premium.

Media around the announcement has been a global hit covering an audience of over 500M, a 2.5M estimated print circulation, 38 individual articles and over 2.5K likes, comments and shares on social media platforms, with a predicted view of 1.75M

Following this we have had 3 commercial conversations with new leads in fashion and accessories which are ongoing with a view to partnering to produce the world first T-rex leather product.

Traditional Leather Partnerships

LGL in 2025 has established a working partnership with another significant fashion brand and is currently continuing to work with three other major fashion brands. These brands are paying LGL to produce samples for assessment and development. Progress is being made confidently, albeit at a measured pace, with these samples being tested and assessed.

To date eight 10x10cm2 samples have been sent out this year to multiple companies, as part of an iterative process their supportive feedback has resulted in notable improvements to the Elemental LeatherTM product to further improve the look, feel and suitability for down-stream processing.

Continuous improvement

LGL production plans are set for significant growth and 3DBT's City-Mix™ media additive will offer substantial savings. Over next 5 years the purchase and use of City-Mix™ from 3DBT will save Lab-Grown Leather Ltd over £500k in tissue production costs, helping to further bring down the cost of the Elemental Leather™ whilst representing an additional revenue stream for 3DBT.

 

Contact Information For further information, please visit: www.bsfenterprise.com

 

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

About BSF Enterprise PLC

BSF Enterprise PLC (BSF) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free platform, BSF aims to deliver sustainable alternatives to traditional materials and meet global demand for environmentally responsible innovations.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPPUMUAUPAPPU
Date   Source Headline
1st Feb 20234:35 pmRNSPrice Monitoring Extension
1st Feb 20232:05 pmRNSSecond Price Monitoring Extn
1st Feb 20232:00 pmRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSUK’s First Fillet of Cultivated Meat Produced
31st Jan 20234:36 pmRNSAnnual Report and Financial Statements
19th Dec 20227:00 amRNS3D Bio-Tissues enters partnership with New Harvest
23rd Nov 20224:40 pmRNSSecond Price Monitoring Extn
23rd Nov 20224:36 pmRNSPrice Monitoring Extension
23rd Nov 20227:00 amRNS3D Bio-Tissues partners with cell growth company
15th Nov 20227:00 amRNSSuccessful Prototypes of Lab-Grown Fillets of Meat
27th Oct 20227:00 amRNS3D Bio-Tissues receives €100,000 grant
21st Sep 20227:00 amRNS3D Bio-Tissues Appoints Business Director
18th Jul 20227:00 amRNSOperational Update
12th Jul 202212:08 pmRNSResults of Annual General Meeting
29th Jun 20227:00 amRNSInterim Financial Statements
17th Jun 20221:43 pmRNSNotice of Annual General Meeting
6th Jun 202210:42 amRNSAppointment of new CFO and opening London Office
17th May 20228:00 amRNSAdmission to Trading and First Day of Dealings
16th May 202210:46 amRNSResults of General Meeting
27th Apr 202212:07 pmRNSConditional Placing to raise £1.75 million
14th Feb 20224:52 pmRNSAnnual Financial Report
24th Dec 202110:58 amRNSAcquisition
16th Aug 20218:13 amRNSProposed Transaction and Suspension of Listing
16th Aug 20217:30 amRNSSuspension - BSF Enterprise Plc
9th Aug 20217:00 amRNSAppointment of Director
4th May 20212:44 pmRNSHalf-year Report
23rd Apr 202112:13 pmRNSHalf-year Report
6th Apr 20218:37 amRNSCorrection Statement
1st Apr 20214:56 pmRNSAGM Statement
1st Apr 20214:54 pmRNSResult of AGM
1st Apr 20217:00 amRNSAnnual Financial Report
1st Apr 20217:00 amRNSNotice of AGM
4th Mar 20213:19 pmRNSAGM Statement
4th Aug 20207:00 amRNSResult of General Meeting 
16th Jul 20207:48 amRNSAcquisition
31st Mar 20207:00 amRNSResult of AGM
26th Mar 202010:49 amRNSNotice Of AGM
3rd Mar 20204:10 pmRNSNotice of Annual General Meeting 2020
3rd Feb 20207:00 amRNSAnnual Financial Report
26th Jul 20198:31 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.